Blue Jet Healthcare Limited
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Healthy return on equity of 19.4%
Concerns1
- Negative free cash flow (βΉ8 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 6 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.03 K Cr | β | βΉ305.00 Cr | β | β | 26.9% | 44.7% | 86.0% |
| Mar 2024 | βΉ712.00 Cr | β | βΉ164.00 Cr | β | β | 19.4% | -1.2% | 2.5% |
| Mar 2023 | βΉ721.00 Cr | β | βΉ160.00 Cr | β | β | 23.5% | 5.6% | -12.1% |
| Mar 2022 | βΉ683.00 Cr | β | βΉ182.00 Cr | β | β | 34.9% | 36.9% | 28.2% |
| Mar 2021 | βΉ499.00 Cr | β | βΉ142.00 Cr | β | β | 41.8% | -7.2% | -2.1% |
| Mar 2020 | βΉ538.00 Cr | β | βΉ145.00 Cr | β | β | 73.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,179 |
| Total Expenses | 739 |
| EBIT / Operating Profit | 440 |
| OPM % | 37% |
| Other Income | 58 |
| Finance Costs | 5 |
| Depreciation & Amortisation | 21 |
| Profit Before Tax | 471 |
| Tax % | - |
| Net Profit / PAT | 352 |
| EPS (βΉ) | 20.33 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Blue Jet Healthcare Limitedthis co. | βΉ8.66 K Cr | βΉ1.03 K Cr | 24.60 | 6.89 | 34.39 | 44.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |